Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral components Demonstrating CREATE's leadership in in vivo immune cell ...

(a) Schematic of the in vivo CAR-T cell therapy process; (b) Clinically validated delivery platforms including LNP-based systems and viral vectors; (c) Emerging future directions for durable and ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

Manufacturing CAR T cell therapy—one of the most powerful weapons against certain blood cancers—has to date involved an elaborate process, through which doctors first extract a patient’s immune cells ...

In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example of the sky-high prices that Big Pharmas are willing to pay for in vivo CAR-T tech. In fact, it was the ...